Selected Publications

He KD, Leonard SM, Mezochow A, Bermudez C, Courtwright A, Blumberg E.: Impact of Donor Radiographic Pneumonia on Posttransplant Recipient Outcomes and Microbiology. Transpl Infect Dis 2026.

Mezochow AK, Clausen E, Whitaker K, Claridge T, Blumberg E, Courtwright AM.: Letermovir should be first-line cytomegalovirus prophylaxis in lung transplant recipients. Am J Transplant 2025.

Torgersen J, Mezochow AK, Newcomb CW, Carbonari DM, Hennessy S, Rentsch CT, Park LS, Tate JP, Bräu N, Bhattacharya D, Lim JK, Mezzacappa C, Njei B, Roy JA, Taddei TH, Justice AC, Lo Re V 3rd.: Severe Acute Liver Injury After Hepatotoxic Medication Initiation in Real-World Data. JAMA Intern Med 184: 943-952, Aug 2024.

Mezochow AK, He KD, Whitaker K, Blumberg E, Crespo MM, Courtwright A.: Letermovir use for cytomegalovirus prophylaxis following lung transplantation: A single-center review. JHLT Open 6: 100149, Aug 2024.

Lo Re V 3rd, Newcomb CW, Carbonari DM, Mezochow AK, Hennessy S, Rentsch CT, Park LS, Tate JP, Bräu N, Bhattacharya D, Lim JK, Mezzacappa C, Njei B, Roy JA, Taddei TH, Justice AC, Torgersen J.: Hepatotoxicity Score: A New Method to Adjust for Use of Potentially Hepatotoxic Medications by Chronic Liver Disease Status. Pharmacoepidemiol Drug Saf 2024.

Mezochow AK, Schaubel DE, Peyster EG, Lewis JD, Goldberg DS, Bittermann T.: Hospitalizations for opportunistic infections following transplantation and associated risk factors: A national cohort study of Medicare beneficiaries. Transpl Infect Dis 2024.

Mezochow AK, Anesi J, West S, Hasz R, Edwards J, Blumberg EA.: COVID-19 in organ donors: An organ procurement organization perspective. Transpl Infect Dis 2024.

Mezochow A, Anesi JA.: The intricate interplay of immunosuppression and outcomes following Gram-negative bloodstream infection in solid organ transplantation. Transpl Infect Dis 2022.

Mezochow AK, Abt PL, Bittermann T.: Differences in Early Immunosuppressive Therapy Among Liver Retransplantation Recipients in a National Cohort. Transplantation 105: 1800-1807, Aug 2021.

Torgersen J, Newcomb CW, Carbonari DM, Rentsch CT, Park LS, Mezochow A, Mehta RL, Buchwalder L, Tate JP, Bräu N, Bhattacharya D, Lim JK, Taddei TH, Justice AC, Lo Re V 3rd.: Protease inhibitor-based direct-acting antivirals are associated with increased risk of aminotransferase elevations but not hepatic dysfunction or decompensation. J Hepatol 2021.